Precision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. Coli
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Precision, Gene-Edited Antimicrobial Targets Difficult-to-Treat E. Coli
An oral, next-generation antimicrobial created using CRISPR-Cas gene editing could one day reduce the severity of a serious, food-borne infections that are generally untreatable with antibiotics. The preclinical findings offer a potential new weapon in the armamentarium against Shiga toxin-producing Escherichia coli (STEC), a bacterium that causes nearly three million acute illnesses worldwide, mostly in children each year. The precision gene th…
A collaboration between Eligo Bioscience and Institut Pasteur presents EB003, a vehicle derived from phages that delivers CRISPR-Cas12a to Escherichia coli O157 to cut stx genes, reduce disease in animal models and prevent the release of Shiga toxin. Read more Precision therapy with phages and CRISPR to combat Escherichia coli O157 without triggering toxins in News.es.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
